{"id":"W4399483084","doi":"10.1136/annrheumdis-2024-eular.1527","title":"AB1428 ADALIMUMAB AND TOCILIZUMAB BIOSIMILARS IN EUROPE: BUDGET-IMPACT AND OPPORTUNITY FOR EXPANDED PATIENT ACCESS","year":2024,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Biosimilar; Adalimumab; Tocilizumab; Medicine; Internal medicine; Rheumatoid arthritis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02821107,0.0005590082,0.0006600331,0.00139794,0.000544159,0.005716939,0.001280331,0.006047195,0.02934487],"category_scores_gemma":[0.02551688,0.0003704671,0.001977905,0.001169207,0.001406275,0.003782575,0.003065605,0.003759394,0.00313605],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004965033,"about_ca_system_score_gemma":0.02404308,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0056244,"about_ca_topic_score_gemma":0.004298231,"domain_scores_codex":[0.9861581,0.007381708,0.001096482,0.0006557786,0.0029666,0.001741341],"domain_scores_gemma":[0.9654556,0.01113383,0.004447944,0.001244375,0.004766924,0.01295129],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.009903867,0.001983475,0.03360372,0.001418666,0.0008193737,0.001714379,0.0005075826,0.005787128,0.008037709,0.07584602,0.2238547,0.6365235],"study_design_scores_gemma":[0.004452108,0.003611646,0.09398267,0.004135252,0.0005630867,0.003404434,0.001601564,0.00761731,0.003359695,0.03220847,0.8448514,0.0002123411],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.137869,0.03996581,0.01770021,0.6736746,0.007095288,0.0006308258,0.004732051,0.0007988162,0.1175335],"genre_scores_gemma":[0.7679891,0.02304133,0.03368461,0.1257942,0.006164671,0.0005973412,0.007193527,0.0004849923,0.03505021],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.02934487,"threshold_uncertainty_score":0.1491962,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07246973880904191,"score_gpt":0.3817156132756152,"score_spread":0.3092458744665733,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}